miR-744-5p inhibited multiple myeloma proliferation by targeting the SOX12/Wnt/β-catenin pathway (Guo et al., 2021), and inhibited the proliferation and metastasis of HCC by targeting TGF-β1 (Huang et al., 2021). Here, TGFB1 is linked to plasma cell myeloma.